Summary
In a prospective randomized study, 90 granulocytopenic febrile patients presenting with a localized infection were treated empirically with ceftazidime alone or in combination with amikacin (1.5 g/day). Two thirds had received selective oral antimicrobial prophylaxis before therapy. The treatment groups were comparable in terms of the depth and duration of granulocytopenia as well the distribution of the infection categories and rate of bacteremia. There was no difference with respect to the final response: 53% for the monotherapy group versus 48% for the combination group, and both regimens appeared to be equally safe. The duration of fever, clinical symptoms, antibiotic therapy, and granulocytopenia were comparable for both treatment groups, and approximately 90% of patients survived the infection. Only one patient given monotherapy required amikacin. It is concluded that aminoglycosides are not necessary for the empiric treatment of infectious complications in granulocytopenic patients if antibacterial prophylaxis has been given before-hand.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Rrferences
Brown AE (1984) Neutropenia, fever, and infection. Am J Med 76: 421–428
Dekker AW, Rozenberg-Arska M, Verhoef J (1987) Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med 106: 7–12
Donnelly JP, Marcus RE, Goldman JM, Cohen J, Worsley AM, Catovsky D, Darrell JH, Want SV, Galton DA (1985) Ceftazidime as first-line therapy for fever in acute leukaemia. J Infect 11: 205–215
EORTC International Antimicrobial Therapy Cooperative Group (1987) Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 317: 1692–1698
Fredlund H, Bjoereman M, Kjellander J, Sjoberg L, Bjorne L, Ohlin A (1990) A 10-year survey of clinically significant blood culture isolates and antibiotic susceptibilities from adult patients with hematological diseases at a major Swedish hospital. Scand J Infect Dis 22: 381–391
Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC, Young LS, You MD (1990) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161: 381–396
Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bamberger BJ, Barlett JG, Saral R, Burke PJ (1987) Oral nor-floxacin for prevention of gram-negative bacterial infection in patients with acute leukemia and granulocytopenia. Ann Intern Med 106: 1–7
Klastersky J (1986) Concept of empiric therapy with antibiotic combinations. Am J Med 80 [Suppl 5 C]: 2–11
National Committee for Clinical Laboratory Standards 1984 (Approved standard M2-A3). Performance standards for antimicrobial disk susceptibility tests. National Committee for Clinical Laboratory Standards, Vilanova, PA
Nováková I, Donnelly JP, Pauw De B (1990) Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia. Scand J Infect Dis 22: 705–711
Nováková I, Donnelly JP, Pauw de B (1991) Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment for presumed bacteremia in febrile granulocytopenic patients. Antimicrob Agents Chemother 35: 672–678
Pauw de B, Williams K, De Neeff J, Bothof T, de Witte T, Holdrinet R, Haanen C (1985) A randomized prospective study of ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother 28: 824–828
Pauw de BE, Donnelly JP, Elves A, Verhagen C, Nováková IRO, Van der Meer JWM (1990) Towards individually tailored empiric antibiotic therapy in febrile granulocytopenic patients. Neth J Med 37: 111–119
Pizzo PA (1987) After empiric therapy: what to do until the granulocyte count comes back. Rev Infect Dis 9: 214–219
Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, Gress J, Longo D, Marshall L, McKnight J, Rubin M, Skelton J, Thaler M, Wesley R (1986) A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315: 552–558
Verhagen C, de Pauw BE, Donnelly JP, Williams KJ, de Witte TJTP (1986) Ceftazidime alone for treating Pseudomonas aeruginosa septicaemia in neutropenic patients. J Infect 13: 125–131
Verhagen CS, de Pauw B, de Witte T, Janssen J, Williams K, de Mulder P, Bothof T (1987) Randomized prospective study of ceftazidime versus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother 31: 191–196
Zeitany RG, El Saghir NS, Santhosh-Kumar CR, Sigmon MA (1990) Increased aminoglycoside dosage requirements in hematological malignancy. Antimicrob Agents Chemother 34: 702–708
Author information
Authors and Affiliations
Additional information
J. P. Donnelly is supported by Glaxo Group Research, London, United Kingdom
Rights and permissions
About this article
Cite this article
Nováková, I.R.O., Donnelly, J.P. & de Pauw, B.E. Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients. Ann Hematol 63, 195–200 (1991). https://doi.org/10.1007/BF01703442
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01703442